In conclusion, this proof-of-concept study demonstrates sustained dysregulation of the immune system in patients with SARS-CoV-2 post-viral fatigue syndrome and that treatment with C1-INH can improve associated symptoms of depression, fatigue, and pain. Here, SERPING1 is linked to major depressive disorder.